Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux in percutaneous coronary intervention
NCT00060554Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Apr 2003
- Modality
- Allosteric Modulators
- Countries
- 3
01
Overview
A Phase 2 trial of fondaparinux in myocardial infarction (MI), coronary artery disease (CAD), sponsored by Merck & Co.. Planned start Apr 2003; status: withdrawn.
02
Drugs
fondaparinux
03
Conditions
myocardial infarction (MI)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00060554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060554.